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Background: Despite the increasing magnitude and impact, there are limited data available on 
the clinical management and in-hospital outcomes of patients who have diabetes mellitus (DM) 
and chronic kidney disease (CKD) at the time of hospitalization for acute myocardial infarc-
tion (AMI). The objectives of our population-based observational study in residents of central 
Massachusetts were to describe decade-long trends (1999–2009) in the characteristics, in-hospital 
management, and hospital outcomes of AMI patients with and without these comorbidities.
Methods: We reviewed the medical records of 6,018 persons who were hospitalized for AMI on 
a biennial basis between 1999 and 2009 at all eleven medical centers in central Massachusetts. 
Our sample consisted of the following four groups: DM with CKD (n=587), CKD without DM 
(n=524), DM without CKD (n=1,442), and non-DM/non-CKD (n=3,465).
Results: Diabetic patients with CKD were more likely to have a higher prevalence of previ-
ously diagnosed comorbidities, to have developed heart failure acutely, and to have a longer 
hospital stay compared with non-DM/non-CKD patients. Between 1999 and 2009, there were 
marked increases in the prescribing of beta-blockers, statins, and aspirin for patients with CKD 
and DM as compared to those without these comorbidities. In-hospital death rates remained 
unchanged in patients with DM and CKD, while they declined markedly in patients with CKD 
without DM (20.2% dying in 1999; 11.3% dying in 2009).
Conclusion: Despite increases in the prescribing of effective cardiac medications, AMI patients 
with DM and CKD continue to experience high in-hospital death rates.
Keywords: diabetes, chronic kidney disease, myocardial infarction
Introduction
Diabetes mellitus (DM) is a major public health concern. The prevalence of DM in 
the US has more than doubled over the past decade, and DM is a major risk factor for 
cardiovascular disease.1 In addition to being at increased risk of developing coronary 
heart disease, patients with diabetes experience higher hospital mortality rates after 
acute myocardial infarction (AMI) than patients without diabetes.2–5 Chronic kidney 
disease (CKD) is also a relatively common condition in the general population with 
more than 26 million American adults estimated to have CKD;6,7 this condition is also 
associated with considerable morbidity and mortality. A recent European report using 
data from a large cardiac registry found that more than one third of patients with CKD 
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have concomitant DM,8 increasing the difficulty of manag-
ing patients with these serious comorbidities. Diagnostic 
and treatment challenges in these high-risk patients pre-
senting with an AMI are further complicated by their more 
advanced presentation, treatment delays, and medication side 
effects.9 Although several studies have described trends in 
the medical management and clinical outcomes of patients 
hospitalized with AMI who have either preexisting DM or 
CKD,2,3,5,9,10 there are extremely limited contemporary data 
available about the characteristics, clinical management, and 
in-hospital outcomes of patients who present with either or 
both of these chronic conditions at the time of hospitalization 
for AMI, especially from the more generalizable perspective 
of a population-based investigation.
The objectives of this population-based study were 
to describe overall differences, and decade-long trends 
(1999–2009), in the characteristics, in-hospital manage-
ment, clinical complications, and in-hospital death rates of 
patients with preexisting DM and CKD, as compared with 
nondiabetic/non-CKD patients, hospitalized with AMI in all 
medical centers throughout central Massachusetts.
Methods
Data from the Worcester Heart Attack Study were used for this 
investigation.11–13 This is an ongoing population-based investiga-
tion describing long-term trends in the epidemiology of AMI 
among residents of the Worcester, MA, metropolitan area (2000 
census =478,000) hospitalized with AMI at all medical centers in 
central Massachusetts.11–13 In brief, the medical records of resi-
dents of this metropolitan area admitted to all eleven hospitals 
in central Massachusetts with a discharge diagnosis of AMI and 
related coronary disease rubrics during the years under study 
were individually reviewed and validated according to prees-
tablished criteria.11 In brief, the diagnosis of AMI was made on 
the basis of criteria developed by the World Health Organization 
and that have been consistently utilized in the Worcester Heart 
Attack Study since its inception. This well-accepted schema uses 
a supportive clinical history, serum enzyme/biomarker eleva-
tions, and serial electrocardiogram changes.11–13 All doubtful 
or “probable” cases of AMI, CKD, DM, or other comorbidities 
were reviewed by the principal investigator in conjunction with 
the project director and then by the study’s senior cardiologists 
for final case classification.11–13 Doubtful or questionable diagno-
ses were defined as those in which there is uncertainty or lack of 
adequate information available to classify the patient as having 
had an AMI.11–13 The present study sample consisted of greater 
Worcester residents hospitalized with AMI on a biennial basis 
between 1999 and 2009.
We classified patients as having a history of either DM 
or CKD, or the absence thereof, based on the review of data 
available in hospital medical records.3,14 Due to the data 
collection efforts of this observational study, and missing 
data on several laboratory values, we classified patients as 
having DM and/or CKD based only on information collected 
and routinely recorded in hospital medical records and not 
on either serum glucose or creatinine findings during their 
index hospitalization. This study was approved by the insti-
tutional review board at the University of Massachusetts 
Medical School.
Data collection
Trained nurses and physicians abstracted demographic and 
clinical data from the medical records of greater Worcester 
residents hospitalized with confirmed AMI. Abstracted infor-
mation included patient’s age, sex, medical history, AMI order 
(initial vs prior), physiologic factors, laboratory test results, 
length of hospital stay, time interval between patient-reported 
acute symptom onset and emergency department arrival, and 
hospital discharge status.11,15 Information about the use of 
important cardiac medications, coronary angiography, per-
cutaneous coronary intervention (PCI), and coronary artery 
bypass (CABG) surgery during the patient’s index hospitaliza-
tion was collected. Development of several significant clini-
cal complications (eg, atrial fibrillation, cardiogenic shock, 
stroke, heart failure) during the patient’s hospitalization was 
defined according to standard criteria.11,13,16,17
Data analysis
Differences in the characteristics of patients with DM 
and/or CKD, as compared with nondiabetic and/or non-CKD 
patients, were examined through the use of chi-square tests 
for discrete variables and analysis of variance for continu-
ous variables; these analytic tests were also used to examine 
potentially changing trends in various patient demographic 
and clinical factors during the years under study. In-hospital 
case-fatality rates, and proportion of patients developing vari-
ous in-hospital clinical complications, in our four comparison 
groups, as well as decade-long trends in these endpoints, were 
calculated by the number of deaths, or clinical complications, 
that occurred during the index hospitalization divided by the 
number of patients admitted to a hospital with confirmed AMI 
during the specific period examined. Decade-long trends in 
the prescribing of several cardiac medications and coronary 
reperfusion/revascularization interventions were also calcu-
lated for the various DM/CKD groups under study through 
the use of chi-square tests for trend.
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Table 1 characteristics of patients hospitalized with aMI by group
Characteristic Diabetic with chronic  
kidney disease  
(n=587), N (%)
Chronic kidney disease  
without diabetes  
(n=524), N (%)
Diabetic without  
chronic kidney disease  
(n=1,442), N (%)
Nondiabetic/non- 
chronic kidney disease 
(n=3,465), N (%)
age (years, mean, sD) 72.6 (11.29) 77.7 (11.9) 70.8 (12.5) 68.6 (15.1)
  ,55 42 (7.2) 24 (4.6) 164 (11.4) 733 (21.2)
  55–64 90 (15.3) 52 (9.9) 263 (18.2) 625 (18.0)
  65–74 165 (28.1) 75 (14.3) 360 (25.0) 623 (18.0)
  75+ 290 (49.4) 373 (71.2) 655 (45.4) 1,484 (42.8)
Female 270 (46.0) 233 (44.5) 677 (47.0) 1,442 (41.6)
Race (White) 499 (92.1) 488 (97.2) 1,253 (92.3) 3,152 (96.2)
Body mass index (kg/m2, mean, sD) 29.2 (6.8) 25.9 (5.8) 29.3 (6.5) 27.2 (5.9)
  ,25 141 (24.0) 206 (39.3) 320 (22.2) 1,082 (31.2)
  25–30 179 (30.5) 167 (31.9) 423 (29.3) 1,071 (30.9)
  $30 267 (45.5) 151 (28.8) 699 (48.5) 1,312 (37.9)
Initial aMI 303 (51.6) 327 (62.4) 891 (61.8) 2,614 (75.4)
Prehospital delay (hours, mean, sD) 2.0 (4.3) 2.0 (3.8) 2.1 (6.9) 2.0 (5.9)
Medical history
  Atrial fibrillation 125 (21.3) 129 (24.6) 199 (13.8) 383 (11.1)
  angina 124 (21.1) 94 (17.9) 278 (19.3) 519 (15.0)
   chronic obstructive pulmonary  
disease
146 (24.9) 113 (21.6) 269 (18.7) 548 (15.8)
  hypertension 526 (89.6) 430 (82.1) 1,199 (83.2) 2,176 (62.8)
  heart failure 342 (58.3) 225 (42.9) 395 (27.4) 504 (14.6)
  Peripheral vascular disease 232 (39.5) 139 (26.5) 299 (20.7) 355 (10.3)
  stroke 134 (22.8) 85 (16.2) 218 (15.1) 273 (7.9)
symptom presentation
  absence of pain 244 (41.6) 194 (37.0) 407 (28.2) 817 (23.6)
  any chest pain 310 (52.8) 293 (55.9) 935 (64.8) 2,403 (69.4)
  Dyspnea 72 (12.3) 57 (10.9) 114 (7.9) 216 (6.2)
  abdominal pain 46 (7.8) 59 (11.3) 107 (7.4) 233 (6.7)
  arm/shoulder pain 43 (7.3) 35 (6.7) 157 (10.9) 474 (13.7)
  left arm pain 78 (13.3) 80 (15.3) 313 (21.7) 926 (26.7)
  Back pain 59 (10.1) 41 (7.8) 189 (13.1) 479 (13.8)
  Palpitations 37 (6.3) 38 (7.3) 106 (7.4) 238 (6.9)
  sweating 148 (25.2) 143 (27.3) 513 (35.6) 1,347 (38.9)
Physiologic variables (median, sD, at hospital admission)
  serum cholesterol (mg/dl) 149.5 (44.5) 159.0 (43.9) 162.0 (48.2) 175.0 (43.9)
  serum glucose (mg/dl) 205.0 (97.8) 132.0 (53.9) 212.0 (92.5) 130.0 (50.7)
   Glomerular filtration rate  
(ml/min/1.73 m2)
29.0 (17.3) 35.3 (19.5) 58.5 (20.4) 62.3 (19.9)
  length of stay (mean, days, sD) 7.1 (6.1) 6.2 (6.5) 6.0 (6.6) 5.1 (4.9)
Abbreviations: aMI, acute myocardial infarction; sD, standard deviation.
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We carried out a series of unadjusted and multivariable-
adjusted logistic regression analyses for purposes of assess-
ing the overall impact of DM and CKD with regard to the 
odds of developing atrial fibrillation, heart failure, and 
cardiogenic shock and dying during the patient’s acute 
hospitalization while controlling for several potentially 
confounding demographic, medical history, and clinical 
factors that have been shown to affect these outcomes. 
Control variables included indicators for the following: 
age, sex, history of various coexisting disorders (angina, 
heart failure, hypertension, or stroke), AMI order (initial vs 
prior), and study year.
Results
characteristics of study patients
A total of 6,018 greater Worcester residents were hospital-
ized with independently confirmed AMI during the years 
under study (Table 1). The average age of these patients 
was 72.4 years, 55.4% were men, 33.7% were diabetic, and 
18.5% had previously diagnosed CKD based on the review 
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of information obtained from hospital medical records. 
There were marked increases between 1999 and 2009 in 
the prevalence of CKD (from 11.8% to 23.3%, P,0.001) 
and DM (from 30.8% to 36.1%, P=0.06); the proportion of 
patients with both conditions approximately doubled from 
6.0% in 1999 to 11.8% in 2009. Our comparative study 
samples consisted of the following: DM with CKD (n=587), 
CKD without DM (n=524), DM without CKD (n=1,442), and 
non-DM/non-CKD (n=3,465).
Overall, the mean age of diabetic patients with CKD was 
73 years; patients with CKD without DM were the oldest, 
with a mean age of 78 years (Table 1). Patients with both 
comorbidities had a higher average body mass index than 
nondiabetics and were much more likely to be overweight. 
Diabetic patients with CKD had a higher prevalence of 
several important cardiovascular comorbidities and chronic 
obstructive pulmonary disease as compared with the other 
three groups (Table 1).
In terms of acute presenting symptoms, diabetic patients 
with and without CKD were less likely to have presented 
with classic anginal symptoms including chest pain, left 
arm pain, shoulder pain, or diaphoresis, and were more 
likely to have complained of dyspnea, than patients without 
DM. Interestingly, almost 40% of patients with previously 
diagnosed CKD, with or without DM, failed to report the 
presence of pain, in the chest or otherwise, at the time of 
hospital admission for AMI. Overall, persons with DM and 
CKD experienced similar delays in seeking acute medical care 
as compared to those without these comorbidities (Table 1). 
Diabetic patients with CKD had a longer average hospital 
stay than non-DM/non-CKD patients (5.0 days vs 4.0 days). 
Serum glucose levels at the time of hospital admission were 
significantly higher in diabetic patients with and without CKD 
as compared to those without DM and CKD (Table 1).
hospital treatment practices
Overall, the prescribing of in-hospital cardiac medications 
was relatively similar in all four patient groups (Table 2). 
However, patients with DM and CKD were more likely to 
have been prescribed calcium channel blockers, diuretics, 
and statins during their acute hospitalization as compared 
with other patient groups (Table 2). Comparing medication-
prescribing practices between 1999 and 2009, there were 
important increases over time in the use of recommended car-
diac medications including angiotensin-converting enzyme 
inhibitors/angiotensin receptor blockers, beta-blockers, 
aspirin, and statins in our four study groups (Figure 1A–D). 
In patients with CKD and without DM, particularly, marked 
increases were noted in the prescribing of beta-blockers, 
statins, and aspirin during the years under study.
Diabetic patients with CKD were less likely to have 
undergone a PCI and CABG surgery in comparison to 
patients without both comorbidities (Table 2). While there 
were marked increases over time in the proportion of hospi-
talized patients undergoing cardiac catheterization and PCI 
in each of our four comparison groups, patients without these 
previously diagnosed comorbidities had a greater increase 
in the receipt of cardiac catheterization and PCI during the 
years under study (Figure 2A and B).
In-hospital clinical complications  
and hospital death rates
Overall, diabetic patients with CKD were more likely to 
have developed heart failure during their acute hospitaliza-
tion as compared to the other diseased groups. Nondiabetic 
patients with CKD were more likely to have developed 
other important in-hospital complications, including atrial 
fibrillation, and to have died during hospitalization for 
AMI (Table 3).
Table 2 hospital management practices by group
Diabetic with chronic  
kidney disease  
(n=587), N (%)
Chronic kidney disease  
without diabetes  
(n=524), N (%)
Diabetic without  
chronic kidney disease  
(n=1,442), N (%)
Nondiabetic/non- 
chronic kidney disease 
(n=3,465), N (%)
Medications
 acei/aRBs 342 (58.3) 265 (50.6) 1,028 (71.3) 2,094 (60.4)
 Beta-blockers 529 (90.1) 454 (86.6) 1,301 (90.2) 3,101 (89.5)
 aspirin 540 (92.0) 465 (88.7) 1,345 (93.3) 3,232 (93.3)
 calcium channel blockers 209 (35.6) 156 (29.8) 392 (27.2) 679 (19.6)
 Digoxin 137 (23.3) 113 (21.6) 337 (23.4) 579 (16.7)
 Diuretics 475 (80.9) 373 (71.2) 926 (64.2) 1,567 (45.2)
 lipid lowering 436 (74.3) 351 (67.0) 1,009 (70.0) 2,353 (67.9)
Interventions
 cardiac catheterization 246 (41.9) 209 (39.9) 870 (60.3) 2,165 (62.5)
 PcI 137 (23.3) 132 (25.2) 565 (39.2) 1,551 (44.8)
 caBg surgery 29 (4.9) 19 (3.6) 113 (7.8) 209 (6.0)
Abbreviations: acei, angiotensin-converting enzyme inhibitors; aRBs, angiotensin receptor blockers; caBg, coronary artery bypass; PcI, percutaneous coronary intervention.
International Journal of Nephrology and Renovascular Disease 2015:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
45
Diabetes and chronic kidney disease
Figure 1 Trends in-hospital medical treatments in patients with myocardial infarction and comorbidities.
Notes: (A–D) Trends in the in-hospital management of patients with acute myocardial infarction according to comorbidities and study year. DM(+) presence of diabetes 
mellitus; DM(-) absence of diabetes mellitus; cKD(+) presence of chronic kidney disease; cKD(-) absence of chronic kidney disease.
Abbreviations: acei, angiotensin-converting enzyme inhibitors; aRBs, angiotensin receptor blockers; DM, diabetes mellitus; cKD, chronic kidney disease.
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Figure 2 Use of coronary interventions in patients with acute myocardial infarction according to comorbidities.
Notes: (A and B) Use of coronary interventions in patients with acute myocardial infarction according to comorbidities and study year. DM(+) presence of diabetes mellitus; 
DM(-) absence of diabetes mellitus; cKD(+) presence of chronic kidney disease; cKD(-) absence of chronic kidney disease.
Abbreviations: PcI, percutaneous coronary intervention; DM, diabetes mellitus; cKD, chronic kidney disease.
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Table 3 In-hospital clinical complications by group
Complication Diabetic with chronic  
kidney disease  
(n=587), N (%)
Chronic kidney disease  
without diabetes  
(n=524), N (%)
Diabetic without  
chronic kidney disease  
(n=1,442), N (%)
Nondiabetic/non- 
chronic kidney* disease 
(n=3,465), N (%)
Atrial fibrillation
 % developing 136 (23.2) 160 (30.5) 278 (19.3) 626 (18.1)
 adjusted ORs# 1.06 (0.84, 1.33)$ 1.27 (1.02, 1.59) 0.94 (0.80, 1.11) 1.0
heart failure
 % developing 363 (61.8) 287 (54.8) 607 (42.1) 1,015 (29.3)
 adjusted ORs 1.78 (1.46, 2.17) 1.36 (1.11, 1.66) 1.18 (1.04, 1.36) 1.0
cardiogenic shock
 % developing 38 (6.5) 36 (6.9) 99 (6.9) 155 (4.5)
 adjusted ORs 1.25 (0.87, 1.82) 1.23 (0.85, 1.78) 1.42 (1.11, 1.82) 1.0
Death
 % developing 79 (13.5) 83 (15.8) 158 (11.0) 289 (8.3)
 adjusted ORs 1.22 (0.93, 1.60) 1.31 (1.01, 1.70) 1.10 (0.91, 1.34) 1.0
Notes: *Referent group: non-diabetic/no chronic kidney disease; #adjusted for age, sex, length of hospital stay, aMI order (initial vs prior), and history of angina, hypertension, 
stroke, heart failure, and year of index hospitalization; $95% confidence intervals.
Abbreviations: ORs, odds ratios; aMI, acute myocardial infarction.
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To more systematically examine the odds of developing 
selected in-hospital complications, we carried out a series of 
multivariable-adjusted regression analyses controlling for 
several potentially confounding factors of prognostic impor-
tance (Table 3). The results of these analyses were consistent 
with our univariate findings showing that diabetic patients 
with CKD were more likely to have developed heart failure as 
compared to those without these comorbidities. Patients with 
DM and without a history of CKD were at greatest odds for 
developing cardiogenic shock, whereas patients with CKD 
and without DM had a markedly higher risk of developing 
atrial fibrillation and dying during hospitalization.
There were important trends in the likelihood of devel-
oping each of these clinical complications during the years 
under study (Figure 3A–C). Patients with CKD with or 
without DM experienced a significant increase in the odds 
of developing atrial fibrillation between 1999 and 2009 
(from 18.8% to 25.8% for those with DM and from 20.0% 
to 30.9% for those without DM). Diabetic patients without 
CKD had a slight increase in the odds of developing heart 
failure over time, whereas patients with CKD without DM 
had a significant decline in the likelihood of developing heart 
failure during the years under study (Figure 3A–C).
Overall, diabetic patients with CKD experienced sig-
nificantly lower in-hospital death rates as compared to 
those with CKD without previously diagnosed DM, who 
had the highest in-hospital death rates (Table 3). The risk 
of dying during hospitalization decreased in each of our 
study groups during the decade-long period under study 
with the exception of those who had both comorbidities 
International Journal of Nephrology and Renovascular Disease 2015:8
Figure 3 In-hospital clinical complications according to comorbidities.
Notes: (A–D) In-hospital clinical complications according to comorbidities and study year. DM(+) presence of diabetes mellitus; DM(-) absence of diabetes mellitus; cKD(+) 
presence of chronic kidney disease; cKD(-) absence of chronic kidney disease.
Abbreviations: DM, diabetes mellitus; cKD, chronic kidney disease.
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previously diagnosed (11.3% dying in 1999; 13.1% in 2009). 
Nondiabetic patients with CKD experienced the greatest 
decline in the risk of dying between 1999 (20.2%) and 2009 
(11.3%) (Figure 3D).
We calculated the overall multivariable-adjusted odds of 
dying for the different groups of patients as compared to those 
without DM and CKD, first calculating unadjusted odds ratios 
(ORs) and then adjusting for several confounding factors of 
prognostic importance and year of the index hospitalization 
(Table 3). After multivariable adjustment, only the ORs for 
patients with CKD without DM were statistically significant 
(OR =1.31; 95% confidence interval 1.01, 1.70) as compared 
to those without these comorbidities. Patients with CKD and 
DM had a slightly higher multivariable-adjusted risk of dying 
as compared to those without these comorbidities.
Discussion
The principal finding of this large population-based study of 
residents of central Massachusetts who were hospitalized at 
all area medical centers with AMI was that, despite marked 
increases in the use of medical and invasive treatments dur-
ing the years under study, and general declines in hospital 
mortality over time, patients with CKD with or without 
DM remained at increased risk of developing important in-
hospital complications and dying as compared to patients 
without either of these important comorbidities.
Our findings are consistent with those of prior studies that 
have shown that diabetic patients with CKD hospitalized with 
AMI are older, more likely to present with a prior myocardial 
infarction, and overweight, and have a variety of additional 
cardiovascular comorbidities present than patients without 
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DM and CKD. Similarly, in a large study that analyzed 
data from more than one million Medicare beneficiaries 
between 1998 and 2001, CKD patients with and without 
DM were older than diabetic patients and those without these 
comorbidities. This study also found that patients with DM 
and CKD presented with the highest prevalence of other 
important comorbidities.7,18
Our results support previous studies that have shown 
that diabetic patients with CKD hospitalized with AMI were 
less likely to report classic angina symptoms but were more 
likely to complain of dyspnea and palpitations, and experi-
enced longer stays in the hospital than patients without these 
comorbidities.19,20 Differences in acute symptom presenta-
tion, and possible reasons that could explain the different 
symptom patterns in diabetic patients with CKD compared 
to those without these comorbidities, need to be explored 
further to enhance the more rapid diagnosis and treatment of 
these high-risk patients.
We found that diabetic patients with CKD were more 
likely to have been prescribed beta-blockers, calcium chan-
nel blockers, digoxin, diuretics, and statins during their acute 
hospitalization for AMI than the other comparison groups. 
Somewhat different prescribing patterns were observed in the 
SYMPHONY (Sibrafiban versus aspirin to Yield Maximum 
Protection from ischemic Heart events post-acute cOroNary 
sYndromes) study, a large international investigation that 
collected data from more than 16,000 patients hospitalized 
with AMI in 37 countries between 1997 and 1999. In this 
study, aspirin, beta-blockers, and statins were less frequently 
prescribed to patients with CKD during hospitalization and 
over a 90-day follow-up period compared to patients without 
CKD.21 Unfortunately, information on the diabetic status of 
study participants was not reported. Similarly, 1,683 patients 
with AMI who were hospitalized at a single large hospital in 
Israel were classified into three categories of CKD: normal, 
moderate, and severe. Compared to patients with normal 
renal function, standard therapy for AMI was underutilized 
in patients with moderate and severe CKD; these individuals 
were also more likely to have developed several in-hospital 
clinical complications including heart failure and atrial 
fibrillation.22 Information about patients with diabetes was not 
reported for participants in this study, and we were unable to 
find other published articles to compare our findings with.
The prescribing of recommended in-hospital cardiac 
medications increased significantly during the years under 
study in all four patient groups. Notably, diabetic patients 
with CKD experienced a greater increase in the prescrib-
ing of beta-blockers, statins, and aspirin than all other 
patient groups. Unfortunately, there is very little literature 
to compare our findings to. Much of the current literature 
has focused on AMI patients with either DM or CKD but 
not on patients with both comorbidities. The majority of the 
studies that have, however, evaluated the use of beneficial 
cardiac medications in AMI patients with either DM or CKD 
have reported an underuse of effective cardiac medications 
in patients with either of these comorbidities compared to 
patients without either CKD or DM.22,23
In the present study, the utilization of PCI and cardiac 
catheterization increased to a greater extent during the 
decade-long period under investigation in diabetic patients 
with CKD than in patients without either of these comorbidi-
ties; on the other hand, less than half of these patients received 
these cardiac interventions. One potential explanation for this 
relatively low percentage is likely due to the high prevalence 
of additional comorbidities in patients with CKD with and 
without DM, which may make clinicians more reluctant to 
treat these complex, high-risk patients. In a recent study using 
data from several national Danish registries, more than 3,100 
patients with and without CKD, and with and without DM, 
were hospitalized with an initial AMI between 2000 and 
2009.24 There was an increase over time in the use of coronary 
angiography in patients with and without CKD and a rela-
tively similar increase in the use of PCI in patients with and 
without CKD during the period under study. Unfortunately, 
information from patients with various combinations of these 
comorbidities was not presented.
Our findings suggest that diabetic patients with CKD 
were more likely to have developed heart failure, whereas 
patients presenting with CKD and without DM experienced 
the highest rates of atrial fibrillation, cardiogenic shock, and 
stroke. Our findings are consistent with those of a large study 
based on a sample of Medicare beneficiaries with different 
cardiovascular diseases who were enrolled and followed 
between 1998 and 2001. Diabetic patients with CKD had 
the highest risk of experiencing heart failure and reinfarction 
during the 2-year follow-up period in comparison to those 
without CKD.7
Similarly, as reported in several studies,25–29 patients 
presenting with CKD and without DM at the time of hos-
pitalization for AMI experienced higher in-hospital death 
rates than other comparison groups in the present study. 
In a recent meta-analysis, data from more than one million 
patients with CKD (120,000 had DM) from the Chronic 
Kidney Disease Prognosis Consortium between 2011 and 
2012 were analyzed. Cardiovascular and all-cause mortality 
were significantly higher in patients with CKD, irrespective of 
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whether or not they had DM, underscoring the importance of 
identifying and treating risk factors for cardiovascular disease 
in patients with CKD.10 In the Cooperative Cardiovascular 
Project, the 1-month death rate after AMI was 44% among 
elderly patients who had moderate renal insufficiency com-
pared with 13% in elderly patients who had normal kidney 
function. Unfortunately, this study did not provide informa-
tion on the diabetes status of this population.25
Patients with DM and CKD in the present study were 
at the highest risk of dying during hospitalization during 
the most recent years under study. Similarly, in a large 
population-based cohort study in Alberta, Canada, more than 
10,000 patients with and without CKD and DM were admit-
ted to the hospital with AMI between 2002 and 2009. Overall 
short-term mortality (within 30 days from admission to the 
hospital) was markedly higher in patients with CKD and DM 
as compared to those without each of these comorbidities.30 
These data reinforce the significant impact of CKD on 
short-term prognosis after AMI and the need for heightened 
surveillance and targeted use of effective treatment regimens 
in these high-risk patients.
The strengths of the present study include our population-
based design that included all patients hospitalized with 
AMI from a large central New England metropolitan area, 
multiple years under study, and the independent validation 
of each possible case of AMI. Study limitations include the 
inability to more systematically measure, and thereby con-
trol for, other clinical factors (eg, severity of disease, CKD 
stage, other physiological variables, or comorbidities) that 
may have affected or mediated the observed relationships 
between CKD and DM in patients hospitalized with AMI. 
Neither the etiology nor the duration of DM and/or CKD, and 
its relationship with other outcomes after hospitalization for 
AMI, could be evaluated from the available data. We also did 
not collect more detailed data on the therapeutic management 
of hospitalized patients, including dosage and frequency of 
selected medications.
Conclusion
The results of this large community-wide study suggest 
that although CKD and DM continue to negatively impact 
short-term prognosis after AMI, increased adoption of effec-
tive medical treatment regimens and coronary reperfusion/
revascularization approaches in these high-risk patients has 
occurred over time with positive results. That being said, 
there remains room for improvement in the medical man-
agement of these high-risk patients. Furthermore, it remains 
important to heighten awareness among health care providers 
about the magnitude of, associations between, and impact 
of these two important and comorbid conditions in relation 
to prognosis after AMI.
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